Related Experiment Video

Updated: Jul 3, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

NFkappaB activation and drug sensitivity in human neoplastic cells treated with anthracyclines

Beata M Gruber1, Elzbieta L Anuszewska, Irena Bubko

  • 1Department of Biochemistry and Biopharmaceuticals, National Medicines Institute, 30/34 Chełmska Str., 00-725 Warsaw, Poland. b-gruber@il.waw.pl

Acta Poloniae Pharmaceutica
|August 1, 2008
PubMed

Insights

Anthracyclines activate nuclear factor kappaB (NFkappaB), influencing cell death. This study shows drug and cell-specific NFkappaB activation by doxorubicin and analogs in melanoma, impacting their cytotoxic effects.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Nuclear factor kappaB (NFkappaB) is a transcription factor regulating cell proliferation and apoptosis.
  • Anthracyclines, potent NFkappaB activators, can induce apoptosis, with their cytotoxic activity often correlating with NFkappaB activation.

Purpose of the Study:

  • To investigate the effects of doxorubicin (DOX) and its analogs (annamycin, WP903) on NFkappaB activity in human melanoma cells.
  • To determine the correlation between NFkappaB activation and cell sensitivity to these anthracyclines in DOX-sensitive (ME18) and DOX-resistant (ME18/R) melanoma cell lines.

Main Methods:

  • MTT assay for cytotoxicity assessment.
  • ELISA test and confocal microscopy for measuring NFkappaB activity.
  • Use of pyrrolidine dithiocarbamate (PDTC) as an NFkappaB inhibitor.

Main Results:

  • Doxorubicin strongly induced NFkappaB in ME18 cells.
  • Annamycin and WP903 induced NFkappaB in ME18/R cells.
  • NFkappaB inhibition by PDTC increased sensitivity to annamycin and WP903 in ME18/R cells but did not affect doxorubicin cytotoxicity in ME18 cells.

Conclusions:

  • NFkappaB activation influences anthracycline cytotoxicity in a drug- and cell-specific manner.
  • The study highlights differential responses of melanoma cells to anthracyclines based on NFkappaB pathway modulation.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...